Solta Medical — Merger or Acquisition (October 2011)
13 slides from Solta Medical's merger presentation, Oct 5, 2011
Slide 1: Pending Acquisition of LipoSonix
Exhibit 99.1 Pending Acquisition of LipoSonix October 5, 2011
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include, but are not limited to, anticipated timing of U.S. Food and Drug Administration and E
Slide 3: LipoSonix Meets Key Acquisition Criteria
LipoSonix Meets Key Acquisition Criteria Key Acquisition Criteria • GAAP/Non-GAAP EPS accretive within a year • Gross margin > 60% • Strong recurring revenue component to business model • Same call point • Unique innovative technology 3
Slide 4: LipoSonix Transaction Analysis
LipoSonix Transaction Analysis Initial Consideration $15,000,000 • Cash payment FDA Clearance of Gen 2 • Payment due upon Gen 2 FDA clearance, assumed end of Q1 2012 $20,000,000 LipoSonix product • Payment reduced if Gen 2 FDA clearance comes after April 2012 • 100% of the incremental increase in ye
Slide 5: LipoSonix Transaction Analysis (cont.)
LipoSonix Transaction Analysis (cont.) • In year 1, the contingent payment will represent a significant percentage of total sales • In year 2, the contingent payment as a percentage of total sales will likely fall substantially • By year 7, the contingent payment as a percentage of total sales will
Slide 6: Investment Highlights
Investment Highlights • Targeting aesthetic and permanent reduction in fat tissue (body contouring), next key market opportunity in aesthetics • Clinically proven results supported by scientific fundamentals • Proprietary High-Intensity Focused Ultrasound (“HIFU”) technology with over 15 issued pate
Slide 7: Compelling Transaction Rationale
Compelling Transaction Rationale Strategic Rationale Financial Rationale • Targets the same customer base • Highly complementary consumables • Large, new, growing market opportunity business model • Adds another highly differentiated • Projected gross margins of over 60% technology to the Solta plat
Slide 8: Aesthetic and Permanent Reduction in Fat Tissue (Body Contouring): The Next Growth Driver in Aesthetics
Aesthetic and Permanent Reduction in Fat Tissue (Body Contouring): The Next Growth Driver in Aesthetics • Aesthetic body contouring device market is the next key device market in aesthetics 3 and has a projected CAGR of 17.7% • Access to physicians increasing due to penetration into medical spas and
Slide 9: LipoSonix: New Solution for Fat
LipoSonix: New Solution for Fat Superficial Devices Surgery/Liposuction Noninvasive Noninvasive Effectively destroys targeted fat Invasive Limited to the skin tissues Surgery-related risks Require repeat Consistent results across Lumpy, asymmetric procedures treatment area results possible Limited b
Slide 10: FDA Outside the United States
LipoSonix Anticipated Regulatory Clearance Milestones Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 FDA Gen 1 FDA Clearance (cleared) Gen 2 FDA Clearance (targeting Q1 2012) Outside the United States Gen 2 EU Clearance (targeting Q4 2011) Gen 2 Rest of World Clearance (targeting be
Slide 11: LipoSonix Gen2 Device
LipoSonix Gen2 Device • 2.7x larger treatment area - speeds treatment time • Improved ergonomics and ease of use • Lighter handheld transducer system (no reticulating arm) • Touch screen interface • Smaller footprint in the physician’s office • Improved serviceability 11
Slide 12: Proficient and Permanent Reduction in Fat Tissue
Proficient and Permanent Reduction in Fat Tissue • Patented HIFU technology creates permanent destruction of targeted fat tissue • Treats at a depth of 11-16 millimeters, destroying the targeted adipose tissue without damaging tissue outside of the intended focal zone • The normal healing process tr
Slide 13: Successful Clinical Studies
Successful Clinical Studies • In clinical trials conducted, subjects, on average, achieved a 2.5 cm waist circumference reduction, with results typically seen in 8 to 12 weeks • Single blind study evaluated across a diverse setting produced significant results • Superior to sham control in reducing